Tessa Brabander

9PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Optical technologyRadiation therapyDigital processor architecturesNeonatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 27, 2026
A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Morticia N Becx, Johannes Hofland, Eric P Krenning

|Jul 01, 2025
Impact of patient size on image quality of OSEM3D and BSREM reconstructions in [68Ga]Ga-DOTA-TATE PET/MR.

Christina P W Cox, Tessa Brabander, Frederik A Verburg

|Jan 17, 2025
First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.

Sui Wai Ling, Quido de Lussanet de la Sablonière, Michael Ananta

|May 21, 2024
How to design a theranostic trial?

Dheeratama Siripongsatian, Quido G de Lussanet de la Sablonière, Frederik Anton Verburg

|Mar 15, 2024
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT.

Christina P W Cox, Tessa Brabander, Erik Vegt

|Oct 05, 2022
Peptide Receptor Radionuclide Therapy.

Johannes Hofland, Tessa Brabander, Frederik A Verburg

Pageof 2